Phenylephrine formulations with improved stability

a technology of phenylephrine and formulation, applied in the direction of granular delivery, organic active ingredients, pill delivery, etc., can solve the problems of product unmarketable in these regions and significantly shorter shelf li

Active Publication Date: 2018-11-20
GLAXOSMITHKLINE CONSUMER HEALTHCARE GMBH & CO KG
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0005]The present invention provides a PHL formulation, preferably in unit dose form, that provides stability sufficient for a shelf life of 24 months, even under high temperature and high humidity conditions. In accordance with the invention, the formulation comprises phenylephrine hydrochloride and a polysaccharide in a weight ratio of at least 1:20, preferably at least 1:30, and most preferably at least 1:40. The polysaccharide used may be maltodextrin. The formulation may also comprise additional active pharmaceutical ingredients (APIs) for cough, cold, and / or congestion, such as diphenhydramine hydrochloride, acetaminophen, dextromethorphan hydrobromide, pheniramine maleate, and chlorpheniramine maleate in conventional amounts relative to the amount of phenylephrine hydrochloride, as well as additional excipients.

Problems solved by technology

OTC preparations intended for sale in Climatic Zones with high ambient temperature and humidity (Climatic Zones 3 (30° C. / 35% relative air humidity) and 4 (30° C. / 70% or greater relative air humidity) therefore may have significantly shorter shelf life which may make the product unmarketable in these regions.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0013]A preparation was made containing 650 mg acetaminophen, 25 mg diphenhydramine hydrochloride, 10 mg phenylephrine hydrochloride, 312 mg maltodextrin, and other excipients per dose. These other excipients included 0.7 mg pharmaceutical-quality dyes, 11.9 mg silicon dioxide, 938 mg natural flavors, 450 mg citric acid, 81 mg sodium citrate, 35 mg calcium phosphate tribasic, and 46 mg high intensity sweeteners. 7500 mg sucrose was added during packaging. The mixture was passed through a roller compactor-mill-sieve equipment train multiple times to achieve particles with an optimal size for further processing. This mixture was further processed into unit dose form.

[0014]When this preparation was subjected to high heat and humidity (40° C. / 75% relative humidity), total phenylephrine hydrochloride degradation (calculated as the % reacted of the labeled content of phenylephrine hydrochloride) was 0.43 at 3 months and 0.81 at 6 months, from an initial degradation of 0.10. In addition, a...

example 2

[0016]A preparation was made containing 650 mg acetaminophen, 20 mg dextromethorphan hydrobromide, 10 mg phenylephrine hydrochloride, 456 mg maltodextrin, and other excipients per dose. These other excipients included 3.7 mg pharmaceutical-quality dyes, 11.9 mg silicon dioxide, 638 mg natural flavors, 705 mg citric acid, 81 mg sodium citrate, 35 mg calcium phosphate tribasic, and 50 mg high intensity sweeteners. 7500 mg sucrose was added during packaging. The mixture was passed through a roller compactor-mill-sieve equipment train multiple times to achieve particles with an optimal size for further processing. This mixture was further processed into unit dose form.

[0017]When this preparation was subjected to high heat and humidity (40° C. / 75% relative humidity), total phenylephrine hydrochloride degradation (calculated as the % reacted of the labeled content of phenylephrine hydrochloride) was 0.44 at 3 months and 0.61 at 6 months, from an initial degradation of 0.21. In addition, a...

example 3

[0019]A preparation is made containing 650 mg acetaminophen, 20 mg pheniramine maleate, 10 mg phenylephrine hydrochloride, 400-600 mg maltodextrin, 50 mg ascorbic acid and other excipients per dose. These other excipients include 0.6-1.58 mg pharmaceutical-quality dyes, 18 mg silicon dioxide, 210-473 mg natural flavors, 650-1000 mg citric acid, 115-180 mg sodium citrate, 35 mg calcium phosphate tribasic, 8-50 mg high intensity sweeteners. An additional 14 g sucrose is added during packaging. The pheniramine maleate and phenylephrine hydrochloride are compacted separately. The mixture is passed through a roller compactor-mill-sieve equipment train multiple times to achieve particles with an optimal size for further processing. This mixture is further processed into unit dose form.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
temperatureaaaaaaaaaa
relative air humidityaaaaaaaaaa
weight ratioaaaaaaaaaa
Login to view more

Abstract

A pharmaceutical composition includes a pharmaceutical polysaccharide and phenylephrine hydrochloride. The ratio of said polysaccharide to phenylephrine hydrochloride is sufficient to dilute the composition such that phenylephrine hydrochloride is stable at high temperature and humidity.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]The present application claims priority to and is a continuation-in-part of U.S. application Ser. No. 13 / 131370 filed on May 26, 2011, which is the national stage filing of PCT / US09 / 67618 filed on Dec. 11, 2009, which claims priority to U.S. Provisional Application Ser. No. 61 / 139,391 filed on Dec. 19, 2008, which are incorporated herein by reference for all purposes.BACKGROUND OF THE INVENTION[0002]This application relates to phenylephrine hydrochloride-containing formulations having improved stability and thus increased shelf life.[0003]Phenylephrine hydrochloride (PHL) is a decongestant frequently used in over-the-counter (OTC) cough and cold preparations. PHL is a reactive molecule that undergoes reactions with numerous excipients commonly used in OTC preparations to form other species, with a corresponding decrease in the amount of active PHL in the product. This can lead to a need to set shorter expiration times than may be consider...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(United States)
IPC IPC(8): A61K31/167A61K31/485A61K31/137A61K9/16A61K9/20A61K31/375A61K31/4402
CPCA61K31/485A61K9/1652A61K9/205A61K31/137A61K31/167A61K31/375A61K31/4402A61K2300/00
Inventor DUNGAN, TIMOTHYWARRINGTON, BRIAN
Owner GLAXOSMITHKLINE CONSUMER HEALTHCARE GMBH & CO KG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap